ClinicalTrials.gg
CompletedNCT07020884Updated Dec 10, 2025

A Study of ZT002 Injection With Subjects With Overweight or Obesity

A Phase 2 interventional study of ZT002 Injection and ZT002 Placebo in Overweight or Obesity, sponsored by Beijing QL Biopharmaceutical Co.,Ltd. Completed at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-10.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing QL Biopharmaceutical Co.,Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Aug 2024, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd — 2 open to participants now, 7 under way, 1 of them phase 3. Obesity · Beijing QL Biopharmaceutical Co.,Ltd.

Enrollment
2nd of 10
303 · median 77
Started
2024
with 1 other
Phase 2
3 of 10
1 open now
Registered
2nd of 10
by date

Among the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, this one is the 2nd largest by enrollment, is one of 2 that started in 2024, is one of 3 in phase 2, and was the 2nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, or all of them as a file.
02

Study summary

This study will evaluate the percentage change from baseline in weight after 24 weeks of treatment with ZT002 Injection in subjects with overweight/obesity.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 303 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Beijing QL Biopharmaceutical Co.,Ltd is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years and ≤ 75 years.
  • ≥28 kg/m², or 24 kg/m2 ≤ BMI \< 28 kg/m2 with at least one comorbidity (pre-diabetes, hypertension, hyperlipidemia, fatty liver, obstructive sleep apnoea syndrome due to overweight, weight-bearing joint pain, etc.)
  • Weight change is not more than 5% with diet and exercise control alone within 3 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of diabetes; or ≥ 6. 5% or fasting blood glucose ≥ 7.0 mmol/L at screening.
  • Have used medicines or treatments that affect weight within 3 months prior to screening.
  • History of acute or chronic pancreatitis.
  • Personal or family (parents, children, and siblings) history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type II (MEN2).
  • History of definite mental disease within 2 years prior to screening or prior suicidal tendency or suicidal behavir; or PHQ-9 scale score is ≥ 15 at screening; or C-SSRS questionnaire is either class 4 or 5 at screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    ZT002 Injection dose 1

    Dose 1 administered subcutaneously (SC), Q2W

    Drug: ZT002 Injection

  • Experimental
    ZT002 Injection dose 2

    Dose 2 administered subcutaneously (SC),Q2W

    Drug: ZT002 Injection

  • Experimental
    ZT002 Injection dose 3

    Dose 3 administered subcutaneously (SC),Q4W

    Drug: ZT002 Injection

  • Experimental
    ZT002 Injection dose 4

    Dose 4 administered subcutaneously (SC), Q4W

    Drug: ZT002 Injection

  • Placebo comparator
    ZT002 Placebo

    administered subcutaneously (SC), Q2W or Q4W

    Drug: ZT002 Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. The percentage change from baseline in weight after 24 weeks of treatment.

    Time frame: baseline, 24 weeks

Secondary outcomes

  1. The proportion of subjects with weight loss of ≥ 5%, ≥ 10%, and ≥ 15% from baseline after 24 weeks of treatment;

    Time frame: 24 weeks

08

Study locations

16 sites
  • Handan First Hospital
    Handan, Hebei 056002, China
  • Hebei Petro China Cental Hospital
    Langfang, Hebei 065000, China
  • First Hospital of Qinhuangdao
    Qinhuangdao, Hebei 066000, China
  • The Fourth Affiliated Hospital Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Henan University of Science & Technology
    Luoyang, Henan 471000, China
  • Luoyang Third People's Hospital
    Luoyang, Henan 471002, China
  • The First Affiliated of Nanyang Medical College
    Nanyang, Henan 473000, China
  • Nanjing Jiangning Hospital
    Nanjing, Jiangsu 210000, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • Tonghua Central Hospital
    Tonghua, Jilin 134000, China
  • Genertec Liaoyou Gem Flower Hospital
    Panjin, Liaoning 124000, China
  • Central Hospital Affiliated to Shandong First Medical University
    Jinan, Shandong 250000, China
  • Zibo Municipal Hospital
    Zibo, Shandong 255400, China
  • Xi'an Daxing Hospital
    Xi’an, Shanxi 710000, China
  • Peking University First Hospital
    Beijing, 100044, China
  • Peking University People's Hospital
    Beijing, 100044, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in May 2025, 8 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 13, 2025
StartActual
Aug 14, 2024
Primary completionActual
May 7, 2025
CompletionActual
May 29, 2025
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07020884
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Aug 14, 2024
Primary completion
May 7, 2025
Completion
May 29, 2025
Last update
Dec 10, 2025

Study contacts

Linong Ji, MD
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZT002

Start the discussion